Clinicians' preferences for managing aneurysmal subarachnoid hemorrhage using endothelin receptor antagonists.

ABSTRACT:

Background

The endothelin receptor antagonist (ERA) clazosentan is being investigated for the medical prevention of cerebral vasospasm and associated complications, such as delayed cerebral ischemia (DCI), after aneurysmal subarachnoid hemorrhage (aSAH). This study quantified how clinicians weigh the benefits and risks of ERAs for DCI prevention to better understand their treatment needs and expectations.

Methods

An online choice experiment was conducted to elicit preferences of neurologists, intensivists, and neurosurgeons treating aSAH in the US and UK for the use of ERAs. The design of the choice experiment was informed by a feasibility assessment (N = 100), one-on-one interviews with clinicians (N = 10), a qualitative pilot (N = 13), and a quantitati

SUBMITTER: Heidenreich S 

PROVIDER: S-EPMC10017541 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature